The Truth About Next Generation Sequencing

• Ambry CEO, Aaron Elliott and Director of Genetic Specialists Laura Panos Smith will discuss Ambry's recent findings that Sanger confirmation along with NGS is required to achieve optimal accuracy for genetic testing results. Read more on Ambry's blog.

   

  Please note: You must attend the full length of the live course and complete the evaluation in order to claim CEUs.

  

  Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.

  

  Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.

Laura Panos Smith | Presenter

Director, Genetic Specialists

Mrs. Panos Smith graduated from University of North Carolina at Chapel Hill with a B.S. in Biology and then received a M.S. in Genetic Counseling from The University of Texas Health Science Center in Houston/MDAnderson. Prior to joining Ambry in 2013, Mrs. Panos Smith worked for the Baylor Health Care System developing the cancer and cardiovascular genetic counseling clinics. She currently serves on the Texas Society of Genetic Counselors board of directors as the ad-hoc licensure chair and the Access & Service Delivery Vice Chair of NSGC. At Ambry, Ms. Panos is the director of the field based genetic specialist team.

 

Aaron Elliott, PhD | Presenter

Chief Executive Officer

Dr. Elliott joined Ambry Genetics in 2008 as a laboratory scientist, working closely on the development of complex molecular diagnostic tests. During his years with the company, Dr. Elliott has held many leadership positions, including Director of Genomic Services, Vice President of Research and Development (R&D), and Chief Scientific Officer.  As a member of the Executive Team, he plays a critical role in product development, quality control, and R&D planning. 

Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation.  As part of this research, Dr. Elliott helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors.

A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine. His thesis involved studying the role of CREB-binding protein in germline and stem cell development